Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-06
2007-11-06
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
10866330
ABSTRACT:
Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.
REFERENCES:
patent: 5318958 (1994-06-01), Kisilevsky
patent: 6004936 (1999-12-01), Kisilevsky
patent: WO96/38166 (1996-05-01), None
patent: WO 01/21188 (2001-03-01), None
patent: WO 02/043742 (2002-06-01), None
Rudinger J., Characteristics of amino acids a components of peptide hormone seqeunces, University Park Press, Baltimore, 1994., pp. 1-7.
Bowie, et al., Deciphering the message in protein seqeunces: tolerance to amino acid substituions (1990) Science, vol. 247 : pp. 1306-1310.
Ancsin et al., “Basic residues in the Carboxy-Terminus of Mouse apoSAA are Involved in Heparin Binding”, Proceedings of the VIIIth International Symposium on Amyloidosis, Rochester, Minnesota, USA Aug. 7-11, 1998 published inAmyloid and Amyloidosis1998, Kyle, R.A. and Gertz, M.A., (eds.) Parthenon Publishing Group Limited, New York (1999), p. 17-19.
Ancsin et al., “Studies Defining the Serum Amyloid A:Heparin Binding Sites” FASEB Summer Conference, Copper Mountain Colorado, Jun. 11-16, 2000 (ABSTRACT).
Ancsin et al., “The Heparin/Heparan Sulfate-binding Site on Apo-serum Amyloid A”, J. Biol. Chem 1999 274:7172-7181.
Ancsin et al., “Laminin interactions with the apoproteins of acute-phase HDL:preliminary mapping of the laminin binding site on serum amyloid A”, Amyloid: Int. J. Exp. Clin. Invest. 1999 6:37-47.
Bagshaw et al., “Characteristics of SAA-Phosphatidylcholine (PC) Liposome Binding to Mouse Macrophages”, Canadian Federation of Biological Sciences, Montreal, Quebec, Jun. 1994 (ABSTRACT).
Banka et al., “Serum amyloid A (SAA) :influence on HDL-mediated cellular cholesterol efflux”, J. Lipid Res. 1995 36:1058-1065.
Bays et al., “Pharmacotherapy for dyslipidaemia -current therapies and future agents”, Expert Opinion on Pharmacotherapy 2003 4(11):1901-1938.
Delsing et al., “Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice”, J. Cardiovasc. Pharmacol. 2003 42(1):63-70.
Ely et al., “The in-vitro influence of serum amyloid A isoforms on enzymes that regulate the balance between esterified and un-esterified cholesterol”, Amyloid J. Protein Folding Disord. 2001 8:169-181.
Ely et al., “Influence of Serum Amyloid A (SAA) on Macrophage AcylCoA:Cholesterol Acyltransferase (ACAT) activity”, VIIIth International Amyloid Symposium, Rochester, Minnesota, U.S.A., Aug. 7-11, 1998 published inAmyloid and Amyloidosis 1998, Kyle, R.A. and Gertz, M.A. (eds.) Parthenon Publishing Group Limited, New York (1999), p. 366-368.
Ganji et al., “Niacin and cholesterol:role in cardiovascular disease (Review)”, J. Nutritional Biochemistry 2003 14:298-305.
Jousilahti et al., “The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project”, Atherosclerosis 2001 156:451-456.
Kajinami et al., “Cholesterol absorption inhibitors in development as potential therapeutics”, Expert Opinion Investig. Drugs 2002 11(6):831-835.
Kinkley et al. “An EM autoradiography and Immunofluorescence Study Examining the Pathway of Serum Amyloid A Through the Macrophage”, Xth International Amyloid Symposium, Tours, France, Apr. 18-22, 2004 (ABSTRACT).
Kinkley et al. “An EM Autoradiography and Immunofluorescence Study Examining the Pathway of Serum Amyloid A Through the Macrophage”, Xth International Amyloid Symposium, Tours, France, Apr. 18-22, 2004.
Kisilevsky et al. “Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1”, J. Lipid Res. 2003 44: 2257-2269.
Kisilevsky et al. “Serum Amyloid A (SAA) Changes HDL's Cellular Affinity: A Clue to SAA's Principal Function”. 81st Annual Meeting U.S.-Canadian Academy of Pathology, Atlanta, Georgia, U.S.A. Mar. 1992, Abstract published in Lab. Invest. 1992 66:107A, (ABSTRACT).
Kisilevsky et al. “Serum Amyloid A Influences the Efflux of Cholesterol from Macrophages”, VIIth International Symposium on Amyloidosis, Kingston, Ontario, Canada, Jul. 1993.
Kisilevsky et al., “Influence of Serum Amyloid A (SAA) on Macrophage Acyl-CoA:Cholesterol Acyltransferase (ACAT) Activity”. 52ndAnnual Meeting of the Canadian Cardiovascular Society, Quebec City, Quebec, Canada, Oct. 19-23, 1999 published inCan. J. Cardiol. 199915 (Suppl D) : 209D (ABSTRACT).
Kisilevsky et al., “The Mechanism of Serum Amyloid A's (SAA) Stimulation of Neutral Cholesterol Ester Hydrolase (NCEH) Activity”. 52ndAnnual Meeting of the Canadian Cardiovascular Society, Quebec City, Quebec, Canada, Oct. 19-23, 1999 published inCan. J. Cardiol. 199915(Suppl D) : 180D (ABSTRACT).
Kisilevsky et al., “Promoting Cholesterol Export from Macrophage Foam Cells—the Mechanism of Action of SAA2.1 and Its Implications”. Canadian Cardiovascular Congress, Oct. 26-30, 2002, Edmonton, Alberta, Canada (ABSTRACT).
Kisilevsky et al., “The promotion of macrophage cholesterol efflux by active domains of serum amyloid 2.1”. Canadian Lipoprotein Conference, Muskoka, Ontario, Canada, Oct. 23-25, 2003 (ABSTRACT).
Kisilevsky et al., “Acute Phase Serum Amyloid A, Cholesterol Metabolism, and Cardiovascular Disease”, Pediatric Pathology and Molecular Medicine 2002 21:291-305.
Kisilevsky, R., “Serum Amyloid A (SAA), a Protein without a Function:Some Suggestions with Reference to Cholesterol Metabolism”, Medical Hypotheses 1991 35:337-341.
Kisilevsky et al., “Acute phase serum amyloid A (SAA) and cholesterol transport during acute inflammation:A hypothesis”, Amyloid: Int. J. Exp. Clin. Invest. 1996 3:252-260.
Kisilevsky et al., “Serum amyloid A changes high density lipoprotein's cellular affinity:A Clue to Serum Amyloid A's Principal Function”, Laboratory Investigation 1992 66:778-785 with attached Erratum (Kisilevsky et al., Laboratory Investigation 1992 67:151.
Knopp, R.H., “Evaluating Niacin in its Various Forms”, Am. J. Cardiol. 2000 86 (supp) :51L-56L.
Kumon et al., “A Longitudinal Analysis of Alteration in Lecithin-Cholesterol Acyltransferase and Paraoxonase Activities Following Laparoscopic Cholecystectomy Relative to Other Parameters of HDL Function and the Acute Phase Response”, Scand. J. Immunol. 1998 48:419-424.
Lee et al., “Minireview:Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors”, Endocrinology 2003 144:2201-2207.
Liang et al., “Serum Amyloid A Is a Chemotactic Agonist at FPR2, a Low-AffinityN-Formylpeptide Receptor on Mouse Neutrophils”, Biochem. Biophys. Res. Commun 2000 270: 331-335.
Liang et al., “Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux”, J. Lipid Res. 1995 36:37-46.
Liang et al., “Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells”, J. Lipid Res. 1996 37:2109-2116.
Lindhorst et al., “Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse”, Biochimica et Biophysica Acta 1997 1339:143-154.
Liuzzo et al., “The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina”, N. Engl. J. Med. 1994 331:417-424.
McCarthy et al., “Potent, Selective, and Systemically-Available Inhibitors of Acyl-Coe
Ancsin John B.
Jia Zongchao
Kisilevsky Robert
Tam Shui-Pang
Licata & Tyrrell P.C.
Mondesi Robert B.
Queen's University at Kingston
LandOfFree
Compositions and methods for treating atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832211